Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YOL104-2
- Development stage
- Preclinical
- Lead developer
- YOLO Immune
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Administration
- Ophthalmic
01
Overview
YOL104-2 is an investigational, bioengineered, trivalent, multifunctional peptibody (a protein-peptide fusion biologic) incorporating a core interferon-mimetic. It is designed as a trivalent interferon-alpha (IFN-α) peptibody. The drug is being developed for the treatment of ocular surface squamous neoplasia (OSSN), a diagnosis encompassing cancerous and precancerous growths on the surface of the cornea and conjunctiva. In October 2026, Visara, Inc. (a majority-owned ophthalmology subsidiary of NovaBridge Biosciences) entered into an asset purchase option agreement with YOLO Immune to acquire worldwide rights to the YOL104 program and to develop and commercialize YOL104-2.
- Other names
- trivalent interferon alpha peptibodytrivalent interferon-alpha peptibody
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on YOL104-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YOL104-2.